P57KIP2 control of actin cytoskeleton dynamics is responsible for its mitochondrial pro-apoptotic effect

Cell Death and Disease

Volumn 3, Issue 5, 2012, Pages

  Kavanagh, E ^a   Vlachos, P ^a   Emourgeon, V ^a   Rodhe, J ^a   Joseph, B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer; Cell migration; Cytoskeleton; p57KIP2

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1C; HEXOKINASE 1; JASPAMIDE; LIM KINASE 1; VOLTAGE DEPENDENT ANION CHANNEL; CDKN1C PROTEIN, HUMAN; CYTOCHALASIN D; DEPSIPEPTIDE; HEXOKINASE; HK1 PROTEIN, HUMAN; LIM KINASE; LIMK1 PROTEIN, HUMAN; STAUROSPORINE; VOLTAGE DEPENDENT ANION CHANNEL 1;

ACTIN FILAMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; HELA CELL; METABOLISM;

ACTIN CYTOSKELETON; APOPTOSIS; CELL MOVEMENT; CYCLIN-DEPENDENT KINASE INHIBITOR P57; CYTOCHALASIN D; DEPSIPEPTIDES; HELA CELLS; HEXOKINASE; HUMANS; LIM KINASES; MITOCHONDRIA; STAUROSPORINE; VOLTAGE-DEPENDENT ANION CHANNEL 1;

EID: 84861556769     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.51     Document Type: Article

References (36)

1. Kavanagh E, Joseph B. The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta 2011; 1816: 50-56.
2. Lam WW, Hatada I, Ohishi S, Mukai T, Joyce JA, Cole TR et al. Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J MedGenet 1999; 36: 518-523.
3. Oya M, Schulz WA. Decreased expression of p57(KIP2)mRNA in human bladder cancer. Br J Cancer 2000; 83: 626-631.
4. Li JQ, Wu F, Usuki H, Kubo A, Masaki T, Fujita J et al. Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol 2003; 23: 1537-1543.
5. Larson PS, Schlechter BL, King CL, Yang Q, Glass CN, Mack C et al. CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 2008; 8: 68.
6. Pateras IS, Apostolopoulou K, Koutsami M, Evangelou K, Tsantoulis P, Liloglou T et al. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer 2006; 119: 2546-2556.
7. Ito Y, Takeda T, Sakon M, Tsujimoto M, Monden M, Matsuura N. Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology 2001; 61: 221-225.
8. Atasoy P, Yilmaz E, Bozdogan O, Ayva S, Batislam E. Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57kip2a). Int Urol Nephrol 2009; 41: 55-60.
9. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995; 9: 650-662.
10. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995; 9: 639-649.
11. Samuelsson MK, Pazirandeh A, Okret S. A pro-apoptotic effect of the CDK inhibitor p57(Kip2) on staurosporine-induced apoptosis in HeLa cells. Biochem Biophys Res Commun 2002; 296: 702-709.
12. Vlachos P, Nyman U, Hajji N, Joseph B. The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway. Cell Death Differ 2007; 14: 1497-1507.
13. Gonzalez S, Perez-Perez MM, Hernando E, Serrano M, Cordon-Cardo C. p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. Cancer Res 2005; 65: 2186-2192.
14. Vlachos P, Joseph B. The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics. Oncogene 2009; 28: 4175-4188.
15. Jia J, Lin M, Zhang L, York JP, Zhang P. The Notch signaling pathway controls the size of the ocular lens by directly suppressing p57Kip2 expression. Mol Cell Biol 2007; 27: 7236-7247.
16. Joseph B, Andersson ER, Vlachos P, Sodersten E, Liu L, Teixeira AI et al. p57Kip2 is a repressor of Mash1 activity and neuronal differentiation in neural stem cells. Cell Death Differ 2009; 16: 1256-1265.
17. Joseph B, Wallen-Mackenzie A, Benoit G, Murata T, Joodmardi E, Okret S et al. p57(Kip2) cooperates with Nurr1 in developing dopamine cells. Proc Natl Acad Sci USA 2003; 100: 15619-15624.
18. Yan Y, Frisen J, Lee MH, Massague J, Barbacid M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 1997; 11: 973-983.
19. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC et al. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997; 387: 151-158.
20. Susaki E, Nakayama K, Yamasaki L, Nakayama KI. Common and specific roles of the related CDK inhibitors p27 and p57 revealed by a knock-in mouse model. Proc Natl Acad Sci USA 2009; 106: 5192-5197.
21. Van Troys M, Huyck L, Leyman S, Dhaese S, Vandekerkhove J, Ampe C. Ins and outs of ADF/cofilin activity and regulation. Eur J Cell Biol 2008; 87: 649-667.
22. Wang W, Mouneimne G, Sidani M, Wyckoff J, Chen X, Makris A et al. The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol 2006; 173: 395-404.
23. Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O et al. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature 1998; 393: 805-809.
24. Yang N, Higuchi O, Ohashi K, Nagata K, Wada A, Kangawa K et al. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 1998; 393: 809-812.
25. Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S, Mizuno K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem 2000; 275: 3577-3582.
26. Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999; 285: 895-898.
27. Xu X, Forbes JG, Colombini M. Actin modulates the gating of Neurospora crassa VDAC. J Membr Biol 2001; 180: 73-81.
28. Posey SC, Bierer BE. Actin stabilization by jasplakinolide enhances apoptosis induced by cytokine deprivation. J Biol Chem 1999; 274: 4259-4265.
29. Cioca DP, Kitano K. Induction of apoptosis and CD10/neutral endopeptidase expression by jaspamide in HL-60 line cells. Cell Mol Life Sci 2002; 59: 1377-1387.
30. Bubb MR, Senderowicz AM, Sausville EA, Duncan KL, Korn ED. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J Biol Chem 1994; 269: 14869-14871.
31. Casella JF, Flanagan MD, Lin S. Cytochalasin D inhibits actin polymerization and induces depolymerization of actin filaments formed during platelet shape change. Nature 1981; 293: 302-305.
32. Gourlay CW, Carpp LN, Timpson P, Winder SJ, Ayscough KR. A role for the actin cytoskeleton in cell death and aging in yeast. J Cell Biol 2004; 164: 803-809.
33. Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci USA 1977; 74: 3735-3739.
34. Arzoine L, Zilberberg N, Ben-Romano R, Shoshan-Barmatz V. Voltage-dependent anion channel 1-based peptides interact with hexokinase to prevent its anti-apoptotic activity. J Biol Chem 2009; 284: 3946-3955.
35. Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW et al. Down-regulation of p57Kip2 induces prostate cancer in the mouse. Cancer Res 2008; 68: 3601-3608.
36. Thoenes L, Gunther M. Novel approaches in anti-angiogenic treatment targeting endothelial F-actin: a new anti-angiogenic strategy? Curr Opin Mol Ther 2008 10: 579-590.